Segal: FAS 106 Impact of Medicare Act Will Not Be Felt in 2003

December 19, 2003 (PLANSPONSOR.com) - The Medicare Prescription Drug, Improvement and Modernization Act of 2003 will have an impact on the way plan sponsors figure their Financial Accounting Standards Act No. 106 (FAS 106) - just not for 2003.

Any questions that plan sponsors may have had about the impact on this year’s FAS 106 disclosures were cleared up in the Financial Accounting Standards Board’s (FASB) staff position letter . In the letter, FASB says it would be premature for any plan sponsor to reflect the recent enhancement of the Medicare Act (See Medicare Bill has Implications for Plan Sponsors ) in its disclosures this year.

For more stories like this, sign up for the PLANSPONSOR NEWSDash daily newsletter.

Plan sponsors though can begin their preparations now for changes to how the cost of retiree health coverage will change their future calculations. Since the Medicare Act introduces a prescription drug benefit under Medicare – Medicare Part D – as well as a federal subsidy to sponsors of retiree health care benefit plans that provide a benefit that is at least actuarially equivalent to Medicare Part D, questions have come up about how FAS 106 will account for these changes.

FAS 106, Employers’ Accounting for Postretirement Benefits Other Than Pensions, addresses employers’ accounting for postretirement health care benefits and the Medicare Act introduces two features that may impact those measurements:

  • a subsidy to a plan’s sponsor based on 28% of the plan’s share of an individual beneficiary’s annual prescription drug costs between $250 and $5,000
  • the opportunity for a retiree to obtain a prescription drug benefit under Medicare.

In an analysis, the Segal Company says it is changes in 2006 that may have an impact on the projected cost of the plan, and therefore, the current liability and expense associated with the plan. Specifically, Segal says:

  • employers that continue to provide retiree prescription drug benefits as the plan exists today will receive a subsidy if the plan is at least as rich in an actuarial sense as the government plan;
  • any changes plan sponsors plan on making to their retiree health benefits in light of the new Medicare benefit would have to be announced to plan participants.

However, in echoing the earlier FASB opinions, Segal says it would be difficult for employers to take advantage of the legislation for 2003. Even still, Segal says plan sponsors should continue to keep an eye on the situation to determine when they have sufficient information to address whether a plan change is necessary.

T. Rowe's Chief Investment Officer Stepping Down

December 18, 2003 (PLANSPONSOR.com) - M. David Testa, the vice chairman and chief investment officer at T. Rowe Price, is resigning his posts.

Testa will hand over the chief investment officer reins to Brian Rogers at the end of year and will retire from the firm and its board of directors in April.Rogers joined the firm in 1982 and has managed the T. Rowe Price Equity Income Fund since its 1985 inception, as well as other institutional equity portfolios. He will retain his portfolio management responsibilities, the firm said in a news release.

For more stories like this, sign up for the PLANSPONSOR NEWSDash daily newsletter.

T. Rowe positioned the move as part of a firm succession plan. Following Testa’s retirement, T. Rowe chairman and president George A. Roche will take over management responsibility for the firm’s investment divisions. “David has had a highly successful investment career spanning more than 30 years with T. Rowe Price, and we respect his desire to bring his career to a close and explore other life interests,” Roche said in the statement. “He has been planning his departure for some time and is retiring at a time when the firm is in a strong position financially and competitively.

Further, upon Testa’s retirement, Rogers will be recommended to replace him as a director on the boards of T. Rowe’s mutual funds.

The changes are all necessary T. Rowe said because the chief investment officer at T. Rowe does not act as the primary investment strategist in determining day-to-day investment strategy or allocations like the same role would at other investment firms. Rather, the CIO at T. Rowe Price provides intellectual leadership, philosophical direction, and a long-term perspective to the investment management process, while also adding an investment perspective to the firm’s corporate decisionmaking. Additionally, the position participates as a member of the firm’s three investment steering committees.

«